Oral anticoagulation in patients with left ventricular thrombus - a systematic review and meta-analysis.
Paul Michael HallerNiema KazemStefan AgewallClaudio BorghiClaudio CeconiDobromir DobrevElisabetta CerbaiErik Lerkevang GroveJuan Carlos KaskiBasil S LewisAlexander NiessnerBianca RoccaGiuseppe M C RosanoGianluigi SavareseRenate B SchnabelAnne Grete SembSamuel SossallaSven WassmannPatrick SulzgruberPublished in: European heart journal. Cardiovascular pharmacotherapy (2024)
In this comprehensive analysis of mainly observational data, the use of DOACs was not associated with a significant difference in stroke or systemic embolism, or thrombus resolution compared to VKA therapy. The use of DOACs was associated with a lower rate of all-cause death and fewer bleeding events. Adequately sized randomized clinical trials are needed to confirm these findings, which could allow a wider adoption of DOACs in patients with LVT.
Keyphrases
- atrial fibrillation
- direct oral anticoagulants
- left atrial
- left ventricular
- venous thromboembolism
- electronic health record
- heart failure
- catheter ablation
- percutaneous coronary intervention
- acute myocardial infarction
- hypertrophic cardiomyopathy
- big data
- single molecule
- cross sectional
- blood brain barrier
- cerebral ischemia